As of the latest Form 4 filed Jun 8, 2026.
What Quest Diagnostics Incorporated insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 11 most recent filings for DGX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-08 | 2026-06-04 | KUPPUSAMY KARTHIK SVP, Clinical Solutions | SSale | −8.15K | $200.00 | $1.63M | Yes (planned) | Form 4 ↗ |
| 2026-06-08 | 2026-06-04 | KUPPUSAMY KARTHIK, SVP, Clinical Solutions | MExercise | +4.83K | $121.81 | $588K | Yes (planned) | Form 4 ↗ |
| 2026-06-08 | 2026-06-04 | KUPPUSAMY KARTHIK, SVP, Clinical Solutions | MExercise | +3.32K | $127.73 | $424K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Davis J. E. CEO and President | SSale | −10.0K | $194.14 | $1.94M | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | SAMAD SAM Executive Vice President & CFO | AAward | +108.00 | $194.70 | $21.0K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | Plewman Patrick SVP for Diagnostic Services | LL | +49.00 | $194.70 | $9.54K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | Gregg Vicky B Director | AAward | +68.00 | $194.70 | $13.2K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | CARTER ROBERT B Director | LL | +7.00 | $194.70 | $1.36K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | Lassiter Wright III Director | LL | +6.00 | $194.70 | $1.17K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | KUPPUSAMY KARTHIK SVP, Clinical Solutions | LL | +39.00 | $194.70 | $7.59K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-20 | DELANEY MARK E SVP & Chief Commercial Officer | LL | +37.00 | $194.70 | $7.20K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also DGX’s full analysis or the market-wide insider trading feed. The tabs above jump to DGX’s other SEC data.
Source: SEC Form 4 filings for DGX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.